NF-κB increases LPS-mediated procalcitonin production in human hepatocytes

Yongfeng Bai, Jun Lu, Ying Cheng, Feng Zhang, Xueyu Fan, Yuanyuan Weng & Jin Zhu

For years, procalcitonin (PCT) has been employed as a diagnostic biomarker for the severity of sepsis and septic shock, as well as for guiding the application of antibiotics. However, the molecular/cellular basis for the regulation of PCT production is not fully understood. In this study, we identified the signalling pathway by which the expression of PCT was induced by lipopolysaccharide in human hepatocytes at the mRNA and protein levels. This expression was dependent on nuclear transcription factor κB (NF-κB), as indicated by a NF-κB binding site (nt −53 to −44) found in the PCT promoter region. We also showed that microRNA-513b (miR-513b) was also able to bind to the 3′-untranslated region (UTR) of the PCT promoter sequence. Meanwhile, the activation of NF-κB down-regulated the expression of miR-513b. In conclusion, we suggest that NF-κB is capable of enhancing the expression of PCT by either directly activating the transcription of the PCT gene or indirectly modulating the expression of its regulatory component, miR-513b. Our results indicate a molecular mechanism responsible for the regulation of PCT production.

Procalcitonin (PCT), the precursor of the hormone calcitonin, comprises 116 amino acids and is present in minute quantities under healthy conditions. The level of PCT has been observed to increase significantly with bacterial infection and correlate to the severity of the infection. Therefore, serum PCT has been considered a powerful biomarker for the diagnosis of bacterial infection. This marker has also been employed successfully to guide the administration of antibiotics. Since the discovery of its association with sepsis in the 1990s, many studies on PCT and its clinical applications have been conducted. However, the molecular details of the regulation of PCT production in relation to bacterial infection remain partially understood.

Nuclear transcription factor κB (NF-κB), an important master transcription factor, is involved in the regulation of numerous components of the host immune response. NF-κB is naturally located in the cytoplasm bound to its inhibitory proteins, known as inhibitors of NF-κB (IκBs). Upon stimulation by various activators, one of which is lipopolysaccharide (LPS), the IκB complex is degraded to release NF-κB protein, and the latter is then allowed to translocate to the nucleus and attach to specific binding site(s) on target genes. As a master transcriptional regulator, NF-κB is responsible for modulating the production of many cellular components, including antimicrobial peptides, cytokines, chemokines, stress-response proteins and anti-apoptotic proteins.

MicroRNAs (miRs) are a group of small, non-coding, single-stranded RNAs that regulate gene expression by base pairing with the untranslated regions (UTRs) of their target genes. Those small molecules are considered the tools for fine tuning the stability of mRNA and consequently affecting the translational outcomes. The miR-513 subfamily belongs to the miR-506–514 cluster. Evidence shows that different members of the miR-513 subfamily (miR-513a/b/c) lead to functional divergences and that miR-513b can affect male sexual maturation by negatively regulating the development stage-related function of DR1. Recent studies have indicated that miR-513b inhibits cell proliferation in testicular embryonal carcinoma and gastric cancer. Furthermore, miR-513b is decreased in cholangiocytes following Cryptosporidium parvum infection or LPS stimulation and is associated with B7-H1 expression. Collectively, these observations suggest that miR-513b plays an important role in regulating the host inflammatory response.

In this study, we conclude that NF-κB signalling activation is necessary for PCT expression in human hepatocytes. On the one hand, NF-κB can directly regulate the production of PCT by binding to its promoter. On the other hand, NF-κB is a negative regulator of miR-513b, which is an inhibitor of PCT expression. Taken together,
NF-κB activation is required for LPS-induced PCT expression. NF-κB is one of the most important regulators of proinflammatory gene expression upon LPS stimulation. Activation of the NF-κB pathway upon LPS treatment was indicated by substantially increased IκBα phosphorylation and degradation as well as NF-κB p65 accumulation in the nuclear fraction in human hepatocytes (Fig. 2a). To explore the role of the NF-κB pathway in LPS-induced PCT expression, we pretreated HepG2 cells with an NF-κB inhibitor, either PDTC or Bay11-7082. The NF-κB inhibitors substantially attenuated the PCT mRNA and protein levels in LPS-stimulated HepG2 cells (Fig. 2b,c). Furthermore, we depleted NF-κB p65 with siRNA in HepG2 cells followed by exposure to LPS. As shown in Fig. 2d, NF-κB p65 inhibition greatly reduced LPS-induced PCT expression at the mRNA level.

Identification of NF-κB binding sites in PCT promoter. Since NF-κB is a transcription factor, we considered whether it promoted PCT expression through direct binding to the PCT gene promoter. Luciferase reporter gene vectors with promoter segments of different lengths were constructed and transiently transfected into HepG2 cells. As shown in Fig. 3a, LPS stimulation significantly increased the luciferase activity with the PCT (−700/+299) and PCT (−202/+299) reporters, respectively. Conversely, LPS could not induce luciferase activity with the PCT (−700/−202) reporter, indicating that the cis elements responsible for LPS-induced PCT expression are located in the PCT promoter region from nt −202 to +299.

To identify NF-κB binding sites, the PCT promoter fragment from nt −202 to +299 was analysed in the TRANSFAC 6.0 database. The putative NF-κB binding sequence GGAACTTTCC (nt −53 to −44) was identified. To confirm the function of this NF-κB binding site in LPS-induced PCT expression, we mutated it in the PCT (−202/+299) reporter to generate the PCT (−202/+299) Mut reporter. Mutation of the NF-κB binding site significantly attenuated LPS-induced luciferase activation compared to the control (wild type) reporter (Fig. 3b). Together, these data indicate that NF-κB enhanced PCT expression upon LPS treatment through direct binding to the PCT promoter.

miR-513b modulates PCT mRNA expression in hepatocytes. Using bioinformatics analysis, we found that PCT is a potential target of miR-513b. To determine whether miR-513b is involved in PCT expression,
we examined the expression of miR-513b upon LPS treatment. Hepatocytes were treated with LPS for the indicated time. The results show that the miR-513b mRNA level decreased gradually after LPS treatment (Fig. 4a). As mentioned above, PCT expression increased in HepG2 cells upon LPS stimulation (Fig. 1a), which was inversely correlated with the change in miR-513b expression. We hypothesized that the correlation between PCT and miR-513b indicated a regulatory association in PCT expression after LPS stimulation in HepG2 cells. To confirm our hypothesis, we enhanced or inhibited miR-513b expression using miR-513b mimics or miR-513b inhibitors, respectively. Ectopic miR-513b expression significantly suppressed PCT mRNA production after LPS stimulation, while miR-513b inhibition enhanced PCT expression compared to the control cells (Fig. 4b). Meanwhile, similar results were also obtained at the protein level (Fig. 4c).

To verify whether PCT is a direct target of miR-513b, we generated several luciferase constructs that contained the 3′-UTR of PCT with either the wild type or mutated putative miR-513b binding site (TTGTGAA to ACGTACC) (Fig. 4d,e). We then transfected HepG2 cells with each reporter construct along with miR-513b or negative control (NC) mimics. The miR-513b mimics significantly decreased the PCT-3′-UTR luciferase activity. In the controls, no difference in luciferase activity was found in HepG2 cells transfected with PCT-3′-UTR Mut compared with the NC mimic (Fig. 4f). These observations suggest that miR-513b binds to the putative binding site in the PCT mRNA 3′-UTR, leading to the inhibition of PCT expression.

**NF-κB activation inhibits miR-513b expression upon LPS stimulation.** Numerous investigations have supported the role of miRs in immune responses and inflammation, which are also known to be regulated by NF-κB14. To test whether the NF-κB pathway is involved in regulating miR-513b expression, we pretreated HepG2 cells with the NF-κB inhibitor PDTC, followed by exposure to LPS for 6 hr. As shown in Fig. 5a, PDTC treatment relieved the inhibitory effect of miR-513b upon LPS stimulation. In addition, the knockdown of NF-κB p65 by specific siRNA significantly alleviated the reduction in miR-513b compared to the control upon LPS stimulation.
stimulation (Fig. 5b). These results demonstrated that NF-κB signalling is required for the inhibition of miR-513b expression upon LPS stimulation.

Discussion

PCT originates from the calcitonin-related polypeptide alpha (CALCA) gene on chromosome 11\textsuperscript{15}. It is produced ubiquitously in response to endotoxins or to mediators released in response to bacterial infections. As such, it has become the mostly widely used biomarker in the management of sepsis around the world. However, the details of the mechanisms regulating PCT expression are not fully understood. In previous research, our team found that miR-125b regulates PCT production in monocytes by targeting STAT3\textsuperscript{16}. However, the release of PCT by monocytes is a transient process and is not a major source of PCT in the circulation\textsuperscript{17}. In septic hamsters, PCT mRNA was significantly increased by various types of parenchymal cells (e.g., hepatocytes), as shown by in situ hybridization\textsuperscript{18}. Moreover, PCT could be detected in the supernatant after stimulating liver slices, which are composed of various cell types, with TNF-α and IL-6\textsuperscript{19}. However, the question of whether parenchymal hepatocytes are capable of synthesizing and secreting PCT remains. Here, we show that LPS treatment strongly induced PCT synthesis at the mRNA and protein levels in human hepatocytes, which suggests that infection-mediated PCT expression is not limited to one type of cell\textsuperscript{20}, as exemplified by parenchymal hepatocytes.

NF-κB is clearly one of the most important regulators of proinflammatory gene expression. NF-κB regulates the synthesis of many cytokines, such as TNF-α, IL-1β, IL-6, and IL-8\textsuperscript{5}. However, whether it is involved in the regulation of PCT expression is unknown. For the first time, we show that the transcription of PCT, whose promoter region had previously been identified\textsuperscript{15}, is under the positive regulation of NF-κB. NF-κB belongs to the category of “rapid-acting” primary transcription factors, which are present in cells in an inactive state and do not require new protein synthesis to become activated. This characteristic may explain the rapid PCT synthesis after LPS treatment.

miRNAs have been indicated to play a key role in the regulation of normal immunity and the inflammation response. For instance, it has been shown that lipomannan from virulent mycobacterium tuberculosis blocks TNF biosynthesis through the induction of miR-125b, which binds to the 3′-UTR region of TNF mRNA and destabilizes the transcript\textsuperscript{21}, miR-155 overexpression led to significantly reduced IL-8 production induced by \textit{H. pylori} infection\textsuperscript{22}. Although miRNAs are important for immunity, the role of miRNAs in the regulation of PCT production remains unexplored. In this study, our luciferase reporter assay revealed that PCT is a direct target downstream of miR-513b and that miR-513b overexpression can negatively regulate the generation of PCT. Our findings indicate that miR-513b plays a key role in the immune response to bacterial infection through PCT production.
The NF-κB signalling pathway regulates the transcription of many miRNAs. Lam et al. suggested that NF-κB signalling may be implicated in the induction of BIC/miR-155 expression in lymphoma cells. Recently, it was reported that the Notch and NF-κB signalling pathways regulate the miR-223/FBXW7 axis in T-cell acute lymphoblastic leukaemia. Using NF-κB inhibitors and siRNAs, we found that the inhibition of miR-513b expression upon LPS treatment is dependent on the activation of NF-κB.

In conclusion, we have demonstrated that the transcription factor NF-κB is involved in the regulation of PCT transcription in LPS-stimulated hepatocytes. On the one hand, NF-κB can directly bind to the promoter region of the CALCA gene to induce PCT production; on the other hand, LPS suppresses the expression of miR-513b by activating NF-κB to upregulate PCT expression (Fig. 6). Our study offers new insight into the immune response activity conferred by miR-513b and the potential mechanisms of PCT production.

**Methods**

**Cell culture and chemicals.** HepG2, L-02, Huh-7 and 293T cells were routinely maintained in DMEM (Life Technologies) supplemented with 10% foetal bovine serum (Life Technologies) and 100 U/ml penicillin in a humidified incubator containing 5% CO₂ at 37°C. NF-κB inhibitors PDTC (ammonium pyrrolidine dithiocarbamate) and BAY11-7082 were purchased from Beyotime (Beijing, China). LPS from the E. coli strain O111:B4 was purchased from Sigma-Aldrich (St. Louis, MO).
PCT protein secretion. PCT protein in the supernatant was analysed after 100-fold concentration using vacuum freeze-drying. Elecsys PCT (Roche) was run on a Cobase 601 analyser, with electrochemiluminescence immunoassay (ECLIA) for protein determination. According to the manufacturers’ information, the detection limit of Elecsys PCT assays is \( \leq 0.02 \) ng/mL, and the functional sensitivity of Elecsys is 0.06 ng/mL. Basal PCT production was below the limit of quantification in unstimulated hepatic cells in vitro.

RNA preparation and quantitative real-time PCR. Total cellular RNA was isolated using TRNzol universal reagent according to the manufacturer’s protocol (Tiangen Biotech, Beijing, China). miRNA was reverse-transcribed using M-MTV117 reverse transcriptase (Takara, Otsu, Japan) with miR-513b-RT and U6-RT primers. cDNA was synthesized using 1 µg of total RNA digested with DNase I and random primer and then subjected to SYBR green (Takara, Otsu, Japan)-based real-time PCR. The amplification primers for miR-513b,
U6, PCT and β-actin are listed in Table 1. The cycling parameters were 94 °C for 90 s and then 40 cycles of 98 °C (10 s), 58 °C (25 s), and 72 °C (25 s), followed by a melting curve analysis. All reactions were performed with four technical replicates and repeated independently three times. The cycle threshold values were normalized to the expression of U6 small nuclear RNA or the housekeeping gene β-actin.

Analysis of nuclear and cytoplasmic proteins by Western blot. Cells were harvested and washed with PBS, followed by centrifugation at 300 × g for 10 min. The cell pellet was lysed with NE-PER nuclear and cytoplasmic extraction reagent according to the manufacturer’s protocol (Thermo Fisher Scientific). The protein concentration was determined by Lowry’s method using bovine serum albumin (BSA) as a standard.

Monoclonal antibodies to NF-κB p65, IκBα, phospho-IκBα, and β-actin were purchased from Cell Signalling, Inc. Monoclonal lamin A/C antibody was purchased from Thermo Fisher Scientific. Western blotting was carried out as previously described. Monoclonal sheep anti-mouse IgG or donkey anti-rabbit IgG horseradish peroxidase-conjugated secondary antibodies were used at a ratio of 1:3000. Proteins were assayed by a chemiluminescence (ECL) reagent using a commercial kit (Tanon Biotechnology, Shanghai, China).

Construction of plasmids. The PCT (NM_001741) promoter fragments nt −700 to +299, −202 to +299, and −700 to −202 were amplified by PCR using human whole-blood genomic DNA as a template and inserted into the KpnI and HindIII sites of the luciferase reporter plasmid pGL3-basic vector (Promega), yielding the reporter constructs PCT (−700/+299), PCT (−202/+299), and PCT (−700/−202), respectively. The primer sequences are listed in Table 1. In the NF-κB point mutants, the potential NF-κB binding site (nt-53 to −44) in the PCT (−202/+299) reporter was replaced with a non-functional sequence using a Site-Directed Mutagenesis Kit (Y easen, Shanghai, China), yielding the reporter construct PCT (−202/+299) Mut. All constructs were confirmed by DNA sequencing.

The 3′-UTR of the PCT gene containing the miR-513b binding site predicted by TargetScan (http://www.targetscan.org/) was inserted into the XhoI and NotI sites of the psiCHECK-2 dual-luciferase reporter vector and designated PCT-3′-UTR (454 bp). The plasmid PCT-3′-UTR Mut containing the mutated binding site of miRNA-513b in the 3′-UTR generated by PCR-based site-directed mutagenesis was also constructed. All constructs generated were verified by DNA sequencing.

Oligonucleotides. The miR-513b mimic and miR-513b inhibitor, as well as the scrambled NC, were chemically synthesized and purified by GENEWIZ (Suzhou, China). The miR-513b mimic is a double-stranded RNA mimic mature endogenous miR-513b, and the miR-513b inhibitor is a single-stranded 2-O-methyl-modified oligo ribonucleotide fragment antisense to miR-513b. The oligonucleotide sequences are listed in Table 1. Human NF-κB/p65 siRNA and NC siRNA were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).

| Name                | Sequence (5′ to 3′)                                      |
|---------------------|--------------------------------------------------------|
| U6-RT               | CGCTTCAGAATTTCGGTGTACAT                                 |
| miR-513b-RT         | GTTGATCCAGATGCGAGGTATTCCACGACTGGATACGACATAAAAAT         |
| U6-F                | GCTTTGGGAGCAGCATAATAATAAAAAT                            |
| U6-R                | CGCTTCAGAATTTCGGTGTCAT                                  |
| miR-513b-F          | GCGCTTCACAAGGAGGTGT                                    |
| miR-513b-R          | GTGAGAAGGTCGAGGTATTCC                                   |
| β-actin-F           | AAGACCTAGAGCAGCTGAC                                    |
| β-actin-R           | AGCAGCTGTGGTGGCAGTGAC                                   |
| PCT-F               | GGAGAGCAGCGAGCAGAGGCC                                   |
| PCT-R               | GTTGAGCATTCTGAGGAGGATGCA                                |
| PCT (−700/+299)-F   | CGGGGTACGAGGAAATCCTTGTAGATCCCTTGCTA                    |
| PCT (−700/+299)-R   | CCAAGCTTGGAGAGGGGATTGAGACTGT                            |
| PCT (−202/+299)-F   | CGGGGTACGAGGAAATCCTTGTAGATCCCTTGCTA                    |
| PCT (−202/+299)-R   | CCAAGCTTGGAGAGGGGATTGAGACTGT                            |
| PCT (−700/−202)-F   | CGGGGTACGAGGAAATCCTTGTAGATCCCTTGCTA                    |
| PCT (−700/−202)-R   | CCAAGCTTAAATGGTGGGGATGTTGGGTCGAGGC                   |
| NC mimic-sense      | UCUCUGCAACACGUCAGCUT                                   |
| NC mimic-antisense  | ACGUGACAGCAGUCCAGGAATT                                 |
| miR-513b-mimic-sense| UCUCAGACGGAGGUCUCAAUAAU                                |
| miR-513b-mimic-antisense | AAUGACACCUCCUUGUGAAUAA                                |
| NC inhibitor        | CAGUCAUUUGUGUGAGUCA                                     |
| miR-513b-inhibitor  | AAUAAUGACACCUCCUUGUGAA                                 |
| PCT-3′-UTR-F        | CTACTTCAGAGGAGCAGCTGAAATGACTCAAGAGACTCA               |
| PCT-3′-UTR-R        | CGGGGGGCGCGCTGAGGGHTATAGAAAATACATTTTT                  |

Table 1. Sequences of Oligonucleotides Used in This Article.
Luciferase reporter gene assay. To identify the NF-κB binding site in the PCT promoter, HepG2 cells (1 × 10^5) were plated in 24-well dishes and cotransfected with 400 ng of the pGL3-reporter plasmid and 20 ng of the pRL-TK Renilla luciferase plasmid using Lipofectamine 3000 transfection reagent (Invitrogen, Carlsbad, CA). After 48 hr, the cells were treated with LPS for 6 hr. Luciferase activity levels were measured with a Dual-Luciferase Reporter Gene Assay Kit (Beyotime, Beijing, China) according to the manufacturer's instructions. Firefly and Renilla luciferase activity levels were determined, and values were normalized to the relevant vector control.

To analyse miR-513b targets, 293 T cells cultured in 24-well plates were transiently cotransfected with 500 ng of luciferase vector PCT-3′-UTR or PCT-3′-UTR Mut and either 100 nM miR-513b mimics or scrambled NC using Lipofectamine 3000. The cells were lysed and the luciferase activity was measured using a Dual-Luciferase Assay after 48 hr.

Transfection with siRNA. HepG2 cells were seeded and transfected in 24-well plates. After seeding HepG2 cells at 1 × 10^5 cells/well, the cells were reverse transfected with 50 nM siRNA or NC siRNA using Lipofectamine 3000 according to the manufacturer's protocol.

Statistical analysis. All data are shown as the mean ± SD (standard deviation). Statistical tests were performed using an unpaired T test (Figs 3 and 4) and two-way ANOVA (Figs 1, 2 and 5) with GraphPad PRISM 6 software. P < 0.05 was considered significant.

References
1. Christ-Crain, M. & Muller, B. Procalcitonin in bacterial infections– hype, hope, or less? Swiss medical weekly 135, 451–460, 2005/31/snow-1169 (2005).
2. Brechot, N., Hekimian, G., Chastre, J. & Luys, C. E. Procalcitonin to guide antibiotic therapy in the ICU. International journal of antimicrobial agents 46(Suppl 1), S19–24, https://doi.org/10.1016/j.ijantimicag.2015.10.012 (2015).
3. Boudma, L. et al. Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 375, 463–474, https://doi.org/10.1016/s0140-6736(09)61879-1 (2010).
4. Vijayan, A. L. et al. Procalcitonin: a promising diagnostic marker for sepsis and antibiotic therapy. Journal of intensive care 5, 51, https://doi.org/10.1186/s40560-017-0246-8 (2017).
5. Tak, P. P. & Firestein, G. S. NF-kappaB: a key role in inflammatory diseases. The Journal of clinical investigation 107, 7–11, https://doi.org/10.1172/jci11830 (2001).
6. Lawrence, T. The nuclear factor NF-kappab pathway in inflammation. Cold Spring Harbor perspectives in biology 1, a001651, https://doi.org/10.1101/cshperspect.a001651 (2009).
7. Gasparini, C. & Feldmann, M. NF-kappab as a target for modulating inflammatory responses. Current pharmaceutical design 18, 5735–5745 (2012).
8. He, L. & Hannon, G. J. MicroRNAs: small RNAs with a big role in gene regulation. Nature reviews. Genetics 5, 522–531, https://doi.org/10.1038/nrg1379 (2004).
9. Sun, Z., Zhang, Y., Zhang, R., Qi, X. & Su, B. Functional divergence of the rapidly evolving miR-513 subfamily in primates. BMC evolutionary biology 13, 255, https://doi.org/10.1186/1471-2148-13-255 (2013).
10. Wang, X. et al. Hsa-miR-513b-5p suppresses cell proliferation and promotes P53 expression by targeting IRF2 in testicular embryonal carcinoma cells. Gene 626, 344–353, https://doi.org/10.1016/j.gene.2017.05.033 (2017).
11. Chen, X. et al. Upregulation of miR-513b inhibits cell proliferation, migration, and promotes apoptosis by targeting high mobility group-box 3 protein in gastric cancer. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine 35, 11081–11089, https://doi.org/10.1007/s13277-014-2405-z (2014).
12. Gong, A. Y. et al. Cryptosporidium parvum induces B7–H1 expression in cholangiocytes by down-regulating microRNA-513. The Journal of infectious diseases 201, 160–169, https://doi.org/10.1093/infdis/jit104 (2010).
13. Zhou, R. et al. NF-kappab P65-dependent transactivation of miRNA genes following Cryptosporidium parvum infection stimulates epithelial cell immune responses. PLoS pathogens 5, e1000681, https://doi.org/10.1371/journal.ppat.1000681 (2009).
14. Ma, X., Becker Buscaglia, L. E., Barker, J. R. & Li, Y. MicroRNAs in NF-kappaB signaling. Journal of molecular cell biology 3, 159–166, https://doi.org/10.1039/mjcb0007 (2011).
15. Hillyard, C. J. et al. Katakalin: a new plasma calcium-lowering hormone. Lancet 1, 846–848 (1983).
16. Zhang, F. et al. miR-125b regulates procalcitonin production in monocytes by targeting Stat3. Microbes and infection 18, 102–108, https://doi.org/10.1016/j.micinf.2015.09.027 (2016).
17. Wiedermann, F. J. et al. Migration of human monocytes in response to procalcitonin. Critical care medicine 30, 1112–1117 (2002).
18. Muller, B. et al. Ubiquitous expression of the calcitonin-gene in multiple tissues in response to sepsis. The Journal of clinical endocrinology and metabolism 86, 396–404, https://doi.org/10.1210/jcem.86.1.7089 (2001).
19. Nijsten, M. W. et al. Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Critical care medicine 28, 458–461 (2000).
20. Linscheid, P. et al. In vitro and in vivo calcitonin gene expression in parenchymal cells: a novel product of human adipose tissue. Endocrinology 144, 5578–5584, https://doi.org/10.1210/en.2003-0854 (2003).
21. Rajaram, M. V. et al. Mycobacterium tuberculosis lipomannan blocks TNF biosynthesis by regulating macrophage MAPK-activated protein kinase 2 (MK2) and microRNA miR-125b. Proceedings of the National Academy of Sciences of the United States of America 108, 17408–17413, https://doi.org/10.1073/pnas.112660108 (2011).
22. Xiao, B. et al. Induction of microRNA-155 during Helicobacter pylori infection and its negative regulatory role in the inflammatory response. The Journal of infectious diseases 200, 916–925, https://doi.org/10.1086/605443 (2009).
23. Lam, L. T. et al. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clinical cancer research: an official journal of the American Association for Cancer Research 11, 28–40 (2005).
24. Kumar, V. et al. Notch and NF-kappaB signaling pathways regulate miR-233/FBXW7 axis in T-cell acute lymphoblastic leukemia. Leukemia 28, 2324–2335, https://doi.org/10.1038/leu.2014.133 (2014).

Acknowledgements
This study was supported by grants from the Medical and Health Technology Projects of Zhejiang Province (2017KY698).
**Author Contributions**
Y.F.B. designed the experiments and wrote the paper. Y.C. and J.L. contributed to the bioinformatics analysis of the sequencing data and the RNA experiments and prepared all figures and tables. F.Z. participated in the interpretation of the results and revision of the paper. X.Y.F. and Y.Y.W. performed the experiments and collected the data. J.Z. proposed and led the project. All authors have read and approved the final manuscript.

**Additional Information**

**Supplementary information** accompanies this paper at https://doi.org/10.1038/s41598-018-27302-7.

**Competing Interests:** The authors declare no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018